# A Study to Evaluate Real-world Brolucizumab Effectiveness and Safety in Japanese Patients With Neovascular Age-related Macular Degeneration (nAMD)

> **NCT06699914** · — · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 438 (actual)

## Conditions studied

- Neovascular Age-Related Macular Degeneration

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT06699914
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2022-09-06
- **Primary completion:** 2023-12-01
- **Final completion:** 2023-12-01
- **Target enrollment:** 438 (ACTUAL)
- **Last updated:** 2024-11-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06699914

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06699914, "A Study to Evaluate Real-world Brolucizumab Effectiveness and Safety in Japanese Patients With Neovascular Age-related Macular Degeneration (nAMD)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06699914. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*